BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.30−0.20 (-2.67%)
Close on Nov 18, 2026Market cap $1.87BP/E –Yield –
BioCryst Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
BioCryst Pharmaceuticals's total assets was $557.85M at Jun 30, 2026. For fiscal 2025 it was $514.16M, up 4.8% from the year before. Over ten years it grew 15.4% a year on average. The highest annual figure on record is $588.15M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $514.16M | +4.8% |
| FY2024 | Dec 31, 2024 | $490.42M | -5.1% |
| FY2023 | Dec 31, 2023 | $516.96M | -6.0% |
| FY2022 | Dec 31, 2022 | $550.00M | -6.5% |
| FY2021 | Dec 31, 2021 | $588.15M | +75.7% |
| FY2020 | Dec 31, 2020 | $334.72M | +91.0% |
| FY2019 | Dec 31, 2019 | $175.28M | +19.4% |
| FY2018 | Dec 31, 2018 | $146.84M | -17.6% |
| FY2017 | Dec 31, 2017 | $178.26M | +98.4% |
| FY2016 | Dec 31, 2016 | $89.85M | -26.6% |
| FY2015 | Dec 31, 2015 | $122.36M | -10.6% |
| FY2014 | Dec 31, 2014 | $136.87M | +180.1% |
| FY2013 | Dec 31, 2013 | $48.87M | -14.9% |
| FY2012 | Dec 31, 2012 | $57.44M | -30.1% |
| FY2011 | Dec 31, 2011 | $82.21M | -24.9% |
| FY2010 | Dec 31, 2010 | $109.45M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $557.85M | +22.0% |
| Q1 FY2026 | Mar 31, 2026 | $465.05M | -3.1% |
| Q4 FY2025 | Dec 31, 2025 | $514.16M | +4.8% |
| Q3 FY2025 | Sep 30, 2025 | $446.42M | -9.1% |
| Q2 FY2025 | Jun 30, 2025 | $457.19M | -3.2% |
| Q1 FY2025 | Mar 31, 2025 | $480.05M | +2.6% |
| Q4 FY2024 | Dec 31, 2024 | $490.42M | -5.1% |
| Q3 FY2024 | Sep 30, 2024 | $491.25M | -6.1% |
| Q2 FY2024 | Jun 30, 2024 | $472.42M | -10.8% |
| Q1 FY2024 | Mar 31, 2024 | $467.89M | -8.2% |
| Q4 FY2023 | Dec 31, 2023 | $516.96M | -6.0% |
| Q3 FY2023 | Sep 30, 2023 | $522.92M | -6.4% |
| Q2 FY2023 | Jun 30, 2023 | $529.89M | +3.8% |
| Q1 FY2023 | Mar 31, 2023 | $509.74M | -3.4% |
| Q4 FY2022 | Dec 31, 2022 | $550.00M | -6.5% |
| Q3 FY2022 | Sep 30, 2022 | $558.59M | +110.2% |
| Q2 FY2022 | Jun 30, 2022 | $510.54M | +84.1% |
| Q1 FY2022 | Mar 31, 2022 | $527.72M | +85.5% |
| Q4 FY2021 | Dec 31, 2021 | $588.15M | +75.7% |
| Q3 FY2021 | Sep 30, 2021 | $265.76M | +50.8% |
| Q2 FY2021 | Jun 30, 2021 | $277.28M | +29.1% |
| Q1 FY2021 | Mar 31, 2021 | $284.43M | +108.2% |
| Q4 FY2020 | Dec 31, 2020 | $334.72M | +91.0% |
| Q3 FY2020 | Sep 30, 2020 | $176.23M | +94.7% |
| Q2 FY2020 | Jun 30, 2020 | $214.71M | +84.5% |
| Q1 FY2020 | Mar 31, 2020 | $136.59M | -4.0% |
| Q4 FY2019 | Dec 31, 2019 | $175.28M | +19.4% |
| Q3 FY2019 | Sep 30, 2019 | $90.50M | -46.2% |
| Q2 FY2019 | Jun 30, 2019 | $116.34M | -14.9% |
| Q1 FY2019 | Mar 31, 2019 | $142.34M | -8.4% |
| Q4 FY2018 | Dec 31, 2018 | $146.84M | -17.6% |
| Q3 FY2018 | Sep 30, 2018 | $168.31M | -12.1% |
| Q2 FY2018 | Jun 30, 2018 | $136.64M | +20.4% |
| Q1 FY2018 | Mar 31, 2018 | $155.37M | +20.0% |
| Q4 FY2017 | Dec 31, 2017 | $178.26M | +98.4% |
| Q3 FY2017 | Sep 30, 2017 | $191.49M | +109.3% |
| Q2 FY2017 | Jun 30, 2017 | $113.51M | – |
| Q1 FY2017 | Mar 31, 2017 | $129.51M | – |
| Q4 FY2016 | Dec 31, 2016 | $89.85M | – |
| Q3 FY2016 | Sep 30, 2016 | $91.50M | – |
See a number that looks wrong?